T
Telesair
Developer of innovative medical technologies enabling healthier living and reducing the burden of care
About Telesair
Telesair is a healthcare technology startup that specializes in the development and distribution of High Flow Oxygen Therapy (HFOT) systems. Their flagship product, Bonhawa, is designed to provide extended flow range of up to 70 liters per minute (lpm) in the US and 80 lpm outside the US. This is a significant advancement in the field of oxygen therapy, as it allows for higher flows than traditional systems, potentially improving patient outcomes.
The company's primary clients are healthcare providers and clinicians who require reliable and efficient oxygen therapy solutions for their patients. The business operates within the global healthcare technology market, with a focus on respiratory care.
Telesair's business model is centered around the sale of their Bonhawa HFOT systems. The company also generates revenue through the sale of disposable components for the system, which need to be replaced regularly for optimal performance and hygiene.
One of the standout features of the Bonhawa system is its user-friendly design. It includes a big, bright display that shows set and delivered flow, a plug protector safety latch, and a quick action display. The system is also easy to clean and disinfect, which can help healthcare providers manage more patients with fewer devices.
In terms of future growth, Telesair is focused on the integration of the latest technology into their devices, with a particular emphasis on connectivity and automation. This could potentially allow for remote monitoring and adjustment of the system, further enhancing its usability and efficiency.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Irvine, United States
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 60.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Respiratory, Pulmonary, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2023 | $22M | $88M | Berkeley Catalyst Fund · Device of Tomorrow Capital · Zhencheng Capital · Honeywell Ventures | ↗ |
Growth signals
Latest recorded traffic for Telesair is 210 monthly website visits, down 95.7% over the last three months. Telesair's team declined 15.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Berkeley Catalyst Fund- DCDevice of Tomorrow Capital
- ZCZhencheng Capital
Honeywell Ventures- UVUltrastar Ventures
ShangBay Capital
Pasaca Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Telesair on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Telesair’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







